Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome

Detalles Bibliográficos
Autores principales: Goyal, Amrita, Narayanan, Damodaran, Wong, Waihay, Laga, Alvaro C., Connell, Nathan T., Ritter, Susan Y., Cobos, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980309/
https://www.ncbi.nlm.nih.gov/pubmed/35391910
http://dx.doi.org/10.1016/j.jdcr.2022.02.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980309/
https://www.ncbi.nlm.nih.gov/pubmed/35391910
http://dx.doi.org/10.1016/j.jdcr.2022.02.022

Ejemplares similares